Results 161 to 170 of about 2,751,693 (208)

Imatinib Resistance in CML

Cancer Letters, 2009
Imatinib is, at present, the first-choice treatment for patients with chronic myeloid leukaemia in chronic phase. Despite the impressive rate of complete haematological response and complete cytogenetical remissions, some cases show primary resistance or relapse after an initial response (secondary or acquired resistance).
Daniela Cilloni   +2 more
exaly   +4 more sources

hOCT 1 and Resistance to Imatinib

Blood, 2005
![ Figure 1. ][1] Figure 1. The pre-imatinib hOCT1 expression level in nonresponders (NRs) and responders (Rs). Imatinib is a substrate for the adenosine triphosphate–binding cassette (ABC) transporters ABCB1 [1][2]-[3][3] and ABCG2 [4][4],[5][5]; however, it is unclear ...
Brian Druker   +2 more
exaly   +3 more sources

Resistance to Imatinib: Mutations and Beyond

Seminars in Hematology, 2010
Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in vitro even prior to the first reports of clinical resistance in patients with chronic myeloid leukemia (CML). The discovery that BCR-ABL is reactivated at the time of resistance and the unveiling of point mutations within the kinase domain of BCR-ABL as a major
Paul, La Rosée, Michael W, Deininger
openaire   +2 more sources

Metabolic Characteristics of Imatinib Resistance in Chronic Myeloid Leukaemia Cells

open access: yesBritish Journal of Pharmacology, 2009
Background and purpose: Early detection of resistance development is crucial for imatinib-based treatment in chronic myeloid leukaemia (CML) patients. We aimed to distinguish metabolic markers of cell resistance to imatinib.
Uwe Christians   +2 more
exaly   +2 more sources

Imatinib resistance in gastrointestinal stromal tumors

Current Oncology Reports, 2005
Conventional chemotherapeutic drugs are ineffective in treatment of gastrointestinal stromal tumors (GISTs). Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients
Lei L, Chen   +9 more
openaire   +2 more sources

Resistance to Imatinib (Glivec): Update on Clinical Mechanisms

Drug Resistance Updates, 2003
Imatinib mesylate, an orally administered 2-phenylaminopyrimidine derivative that inhibits BCR/ABL tyrosine kinase activity, has shown great promise in the treatment of chronic myelogenous leukemia (CML). This small molecule, tyrosine kinase inhibitor, has also been shown to be effective against metastatic gastrointestinal stromal tumors (GISTs ...
Ellen Weisberg, James D Griffin
exaly   +3 more sources

Clinical resistance to imatinib: mechanisms and implications

Hematology/Oncology Clinics of North America, 2004
Although responses to imatinib in chronic phase chronic myelogenous leukemia have been durable in most cases, most patients in advanced disease develop resistance and relapse after a short duration of therapy. The mechanisms of drug resistance are diverse, but in most cases, mutations are found at the time of resistance that change amino acids within ...
Hochhaus, A., Hughes, T.
openaire   +3 more sources

Successful Overcoming of Imatinib Resistance by Synergistic Effect of Imatinib and Simvastatin in Imatinib Resistant Chronic Myelogenous Leukemia Cell Line.

Blood, 2007
Abstract Statins (HMG-CoA reductase inhibitors) are known to show antiproliferative effects and are anticipated as a potential drug in the treatment of malignancies including acute myelogenous leukemia (AML) and multiple myeloma (MM). Using cell proliferation assays, we determined the effects of simvastatin in CML cells.
Bora Oh   +4 more
openaire   +1 more source

Home - About - Disclaimer - Privacy